Clicky

Federal Circuit Endorses the Doctrine of Equivalents Once more for Lilly’s ALIMTA®:  Completely different Modification, Identical Outcome

Federal Circuit Endorses the Doctrine of Equivalents Again for Lilly’s ALIMTA®:  Different Amendment, Same Result

Back in July we wrote about the doctrine of equivalence (DOE) in bio / pharmaceutical cases in general and the ongoing DOE saga in Lilly’s ALIMTA® Litigation specifically. Last week the Federal Circuit wrote a new chapter and issued a non-priority decision in the Eli Lilly and Company v Apotex, Inc. case. Didn’t it all … Read more